PCM
FOLD

Penserra Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Penserra Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,100
Closed -$58K – 1425
2021
Q3 		$58K Buy
6,100
+45
+0.7% +$460 ﹤0.01% 1009
2021
Q2 		$58K Buy
6,055
+150
+3% +$1.46K ﹤0.01% 962
2021
Q1 		$58K Sell
5,905
-120
-2% -$1.86K ﹤0.01% 793
2020
Q4 		$139K Sell
6,025
-2,019
-25% -$41.3K ﹤0.01% 575
2020
Q3 		$113K Sell
8,044
-2,190
-21% -$31.9K ﹤0.01% 476
2020
Q2 		$154K Buy
+10,234
New +$125K 0.01% 491

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Penserra Capital Management's FOLD Position: Q4 2021 in Review

Penserra Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 6,100 shares — an estimated $58K sold.

Penserra Capital Management first reported a position in FOLD in Q2 2020 and held it in 6 quarters. The position peaked at $154K in Q2 2020. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

  • Penserra Capital Management reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 6,100 Amicus Therapeutics shares in Q4 2021, an estimated $58K.
  • Penserra Capital Management first reported a position in Amicus Therapeutics in Q2 2020 and held it in 6 quarters.
  • Penserra Capital Management's Amicus Therapeutics position peaked at $154K in Q2 2020.
  • 224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.